- Home
- PBPB vs DRUG Comparison
PBPB vs DRUG Comparison
Compare PBPB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- DRUG
- Stock Information
- Founded
- PBPB 1977
- DRUG 2019
- Country
- PBPB United States
- DRUG United States
- Employees
- PBPB N/A
- DRUG N/A
- Industry
- PBPB Restaurants
- DRUG Pharmaceuticals and Biotechnology
- Sector
- PBPB Consumer Discretionary
- DRUG Health Care
- Exchange
- PBPB Nasdaq
- DRUG Nasdaq
- Market Cap
- PBPB 305.0M
- DRUG 345.6M
- IPO Year
- PBPB 2013
- DRUG N/A
- Fundamental
- Price
- PBPB $17.01
- DRUG $50.15
- Analyst Decision
- PBPB Buy
- DRUG Strong Buy
- Analyst Count
- PBPB 3
- DRUG 9
- Target Price
- PBPB $17.37
- DRUG $81.67
- AVG Volume (30 Days)
- PBPB 1.9M
- DRUG 81.8K
- Earning Date
- PBPB 11-06-2025
- DRUG 08-11-2025
- Dividend Yield
- PBPB N/A
- DRUG N/A
- EPS Growth
- PBPB N/A
- DRUG N/A
- EPS
- PBPB 0.35
- DRUG N/A
- Revenue
- PBPB $469,138,000.00
- DRUG N/A
- Revenue This Year
- PBPB $5.28
- DRUG N/A
- Revenue Next Year
- PBPB $4.30
- DRUG N/A
- P/E Ratio
- PBPB $49.14
- DRUG N/A
- Revenue Growth
- PBPB N/A
- DRUG N/A
- 52 Week Low
- PBPB $7.27
- DRUG $0.94
- 52 Week High
- PBPB $17.04
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- PBPB 58.93
- DRUG 64.29
- Support Level
- PBPB $12.38
- DRUG $44.25
- Resistance Level
- PBPB $17.04
- DRUG $49.38
- Average True Range (ATR)
- PBPB 0.22
- DRUG 3.50
- MACD
- PBPB -0.61
- DRUG 0.15
- Stochastic Oscillator
- PBPB 99.82
- DRUG 88.01
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.